Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
Bioorg Med Chem. 2020 Sep 1;28(17):115634. doi: 10.1016/j.bmc.2020.115634. Epub 2020 Jul 9.
Single domain antibody fragments (sdAbs) exhibit a rapid tumor uptake and fast blood clearance amenable for labeling with F (t = 110 min) but suffer from high kidney accumulation. Previously, we developed a method for F-labeling of sdAbs via trans-cyclooctene (TCO)-tetrazine (Tz) inverse electron demand Diel's Alder cycloaddition reaction (IEDDAR) that incorporated a renal brush border enzyme (RBBE)-cleavable linker. Although >15 fold reduction in kidney activity levels was achieved, tumor uptake was compromised. Here we investigate whether replacing the [F]AlF-NOTA moiety with [F]fluoronicotinyl would rectify this problem. Anti-HER2 sdAb 5F7 was first derivatized with a TCO-containing agent that included the RBBE-cleavable linker GlyLys (GK) and a PEG chain, and then subjected to IEDDAR with 6-[F]fluoronicotinyl-PEG-methyltetrazine to provide [F]FN-PEG-Tz-TCO-GK-PEG-5F7 ([F]FN-GK-5F7). For comparisons, a control lacking GK linker and 5F7 labeled using residualizing N-succinimidyl 3-guanidinomethyl-5-[I]iodobenzoate (iso-[I]SGMIB) also were synthesized. Radiochemical purity, affinity (K) and immunoreactive fraction of [F]FN-GK-5F7 were 99%, 5.4 ± 0.7 nM and 72.5 ± 4.3%, respectively. Tumor uptake of [F]FN-GK-5F7 in athymic mice bearing subcutaneous SKOV3 xenografts (3.7 ± 1.2% ID/g and 3.4 ± 1.0% ID/g at 1 h and 3 h, respectively) was 2- to 3-fold lower than for co-injected iso-[I]SGMIB-5F7 (6.9 ± 1.9 %ID/g and 8.7 ± 3.0 %ID/g). However, due to its 6-fold lower kidney activity levels, tumor-to-kidney ratios for [F]FN-GK-5F7 were 3-4 times higher than those for co-injected iso-[I]SGMIB-5F7 as well as those observed for the F conjugate lacking the RBBE-cleavable linker. Micro-PET/CT imaging of [F]FN-GK-5F7 in mice with SKOV-3 subcutaneous xenografts clearly delineated tumor as early as 1 h with minimal activity in the kidneys; however, there was considerable activity in gallbladder and intestines. Although the tumor uptake of [F]FN-GK-5F7 was unexpectedly disappointing, incorporating an alternative RBBE-cleavable linker into this labeling strategy may ameliorate this problem.
单域抗体片段(sdAb)表现出快速的肿瘤摄取和快速的血液清除,适用于 F(t=110 分钟)标记,但肾脏积累较高。 此前,我们开发了一种通过反电子需求 Diel 的 Alder 环加成反应(IEDDAR)对 sdAb 进行 F 标记的方法,该方法包含肾脏刷状缘酶(RBBE)可切割的接头。 尽管实现了 >15 倍的肾脏活性水平降低,但肿瘤摄取受到了损害。 在这里,我们研究了用[F]氟代烟酰基代替[F]AlF-NOTA 部分是否可以解决此问题。 首先用包含 RBBE 可切割接头 GlyLys(GK)和 PEG 链的含 TCO 的试剂衍生抗 HER2 sdAb 5F7,然后用 6-[F]氟代烟酰基-PEG-甲基四嗪对其进行 IEDDAR,以提供[F]FN-PEG-Tz-TCO-GK-PEG-5F7([F]FN-GK-5F7)。 作为对照,还合成了缺乏 GK 接头和使用残留的 N-琥珀酰亚胺基 3-胍基甲基-5-[I]碘代苯甲酸酯(iso-[I]SGMIB)标记的对照物。[F]FN-GK-5F7 的放射化学纯度、亲和力(K)和免疫反应性分数分别为 99%、5.4±0.7 nM 和 72.5±4.3%。 在皮下接种 SKOV3 异种移植瘤的荷瘤裸鼠中,[F]FN-GK-5F7 的肿瘤摄取(分别在 1 h 和 3 h 时为 3.7±1.2%ID/g 和 3.4±1.0%ID/g)比共注射的 iso-[I]SGMIB-5F7(6.9±1.9%ID/g 和 8.7±3.0%ID/g)低 2-3 倍。 然而,由于其肾脏活性水平低 6 倍,[F]FN-GK-5F7 的肿瘤与肾脏比值比共注射的 iso-[I]SGMIB-5F7 以及缺乏 RBBE 可切割接头的 F 缀合物高 3-4 倍。 用[F]FN-GK-5F7 对皮下接种 SKOV-3 异种移植瘤的小鼠进行微 PET/CT 成像,在 1 h 时可早期清晰地描绘肿瘤,而肾脏中的活性最小;然而,胆囊和肠道中有相当多的活性。 尽管[F]FN-GK-5F7 的肿瘤摄取令人意外地令人失望,但将替代的 RBBE 可切割接头纳入这种标记策略可能会改善这一问题。